Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study

Gaetano Lombardi, A. Colao, P. Marzullo, B. Biondi, E. Palmieri, S. Fazio, V. Trischitta, C. Battista, S. Giovanni Rotondo, R. Cozzi, M. Barausse, G. Faglia, M. Arosio, G. Giordano, M. Giusti, F. Mantero, G. Arnaldi, E. Martino, M. Gasperi, N. SicoloC. Martini, R. Valcavi, M. Zini

Research output: Contribution to journalArticlepeer-review

Abstract

We report the results of a prospective Italian multi-center study of the effects of lanreotide, a slow-release somatostatin analog, on left ventricular morphology and function and on the prevalence of ventricular arrhythmic events in 19 patients with active, newly diagnosed, uncomplicated acromegaly. Cardiac features were evaluated with Doppler-echocardiography and 24-h Holter ECG monitoring at baseline and after 6 months of lanreotide therapy. Fifteen patients (78.9%) had left ventricular hypertrophy. Lanreotide treatment significantly decreased the left ventricular mass (127.8±6.9 vs 140.7±7.1 g/m2, p50/24 h) occurred in 16.6% of patients and were unaffected by treatment. Differently, ventricular premature beats (>50/24 h) occurred in 33.3% of patients before treatment vs 16.5%, after treatment. In conclusion, lanreotide reduced the left ventricular mass, and improved ventricular filling and ventricular arrhythmic profile.

Original languageEnglish
Pages (from-to)971-976
Number of pages6
JournalJournal of Endocrinological Investigation
Volume25
Issue number11
Publication statusPublished - Dec 2002

Keywords

  • Acromegaly
  • Arrhythmias
  • GH
  • Hypertrophy
  • IGF-I
  • Lanreotide

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study'. Together they form a unique fingerprint.

Cite this